

# Conflict of Interest Disclosure Form

## *EAS Conflict of Interest Disclosure Policy*

The European Atherosclerosis Society (EAS) wishes to promote independence, objectivity, scientific rigor and a fair balance of representation, in all its activities.

The EAS have adopted a Conflict of Interest (COI) Disclosure Policy for the purpose of providing guidance and avoiding conflicts of interest within the Society.

In order to ensure this, individuals participating in the organization of activities on behalf of the Society are expected to disclose their financial or in-kind relationships both with health industry that develop, manufacture, distribute or sell health care materials or services, or other organizations that could represent a potential COI. Such relationships exclude personal or family medical care. Full disclosure is expected even when it is not clear whether a relationship or affiliation constitutes a conflicting interest.

EAS recognizes that these relationships do not necessarily imply bias or decrease the value of participation in professional activities.

Disclosure of these relationships is necessary for others to make an informed decision about the impact of the disclosed relationship. For instance, this may be relevant in the context of educational activities of the EAS.

Those requested to complete the form below include: all EAS Officers and members of the Society's Committees, members of EAS Consensus Position Paper expert panels, and EAS Course Organizers. The forms will be updated annually. The completed forms will be archived at the Society's Administrative Offices and made publicly available on the Society's website. Course and Congress Faculty will be required to present a slide summarizing any COI disclosures before their presentation.

**Please disclose all relationships over the previous three calendar years (2017-2019).**

**If you do not have any conflicts of interest to disclose please check the appropriate box, page 3.**

Nature of relationship or affiliation	Company Name	Company Name	Company Name
<b>1. Equity interests</b> Equity interests (or entitlement to same) of stocks, stock options, royalties, etc., including income from patents or copyrights			
<b>2. Director or employee</b> Service as a director or employment by a commercial organisation, whether or not remuneration is provided for such service			
<b>3. Owner enterprise</b> Sole ownership, partnership, or principal of a commercial enterprise			
<b>4. Ownership of patent(s)</b>			
<b>5. Royalties</b> Receipt of royalties, including for intellectual property, such as a device or a diagnostic tool			
<b>6. Company consultant</b> Consultant to company including positions on medical or scientific advisory boards			
<b>7. Company speaker honorarium</b> Honoraria for speaking at company sponsored meetings or events.			

<b>8. Trial participation</b> Participation in clinical trials			
<b>9. Fellowship, travel grants</b> Support in the form of fellowships, travel grants, gifts, in-kind donations, etc.			
<b>10. Research grants</b> Research grants, partial or full salary support from a commercial organisation for self or employees for whom you are managerially responsible (i.e. laboratory technical/research fellow for whom you are managerially responsible).			
<b>11. Publications</b> Manuscripts have been published in collaboration with non-academic co-author of the following scientific articles			
<b>12. Other - please indicate</b> Any other type of financial or other relationship	<b>Company</b>	<b>Conflict Type</b>	

I do not have any existing or known future financial relationships or commercial affiliations to disclose.

**Declaration:**

I have answered fully and to the best of my ability and will update this form promptly if my circumstances change.

**Digital Signature** (Adobe reader only)  
 Preferred option, sign, save and send by email

OR

**Print and sign**

Signature  \_\_\_\_\_

Name printed clearly \_\_\_\_\_

Date \_\_\_\_\_

#### 4. Ownership of patent(s)

1. Pichette A, **Gaudet D**. Process for preparing natural product derivatives from plants in a single step. Brevet émis 6,280,778 (États-Unis), 28 août 2001. Brevet émis 2,288,361 (Canada), November 2, 1999.
2. Hudson TJ, Vohl MC, Brewer C, Morgan K, **Gaudet D**. Peroxisome proliferator-activated receptor alpha and disorder of lipid metabolism. Brevet émis 6,544,743 (États-Unis), April 8, 2003
3. Hudson TJ, Engert JC, **Gaudet D**, Lepage P, Vohl MC, Williams SM. Methods for predicting susceptibility to obesity and obesity-associated health problems. 20030032099, April 4, 2002
4. **Gaudet D**, Rioux J, Arsenault S, Hudson TJ, Daly M. Glycerol as a predictor of glucose tolerance. (Séquence génétique) Brevet émis 6,743,579 (États-Unis), June 1, 2004.
5. Engert J, Vohl MC, Brewer C, Morgan K, **Gaudet D**, Hudson TJ. Very low density lipoprotein receptor polymorphisms and uses therefor. Brevet émis 6,833,240 (États-Unis), December 21, 2004.
6. Hamet P, Merlo E, Tremblay J, **Gaudet D**, Seda O, Broeckel U, Kotchen TA, Cowley AW Jr. Hypertension with and without metabolic syndrome present as distinct clinical and genetic entities in French-Canadians. Demande de brevet 60/691,843 (États-Unis), June 20, 2005.
7. **Gaudet D**, Paradis F. Méthode de dépistage de porteurs de maladies récessives. Demande de brevet 2,610,057 (Canada), November 7, 2007.
8. Paradis F, **Gaudet D**. Méthode de détection du staphylocoque doré résistant à la méthicilline (SARM). Demande de brevet 2,569,552 (Canada) 23 novembre 2006. PCT/CA2007/002122 (International), November 23, 2007.
9. **Gaudet D**, Santure M, Brisson D, Tremblay G. Method for predicting and detecting intolerance to an hypolipidemic agent. Méthode de détection de l'intolérance au traitement avec un hypolipidémiant. Demandes de brevet 2,640,415 (Canada)12/245,088 (États-Unis), October 3, 2008.
10. De Wal J, **Gaudet D**. Use of lipoprotein lipase (LPL) in therapy. Patent application PCT/NL2010/050294 (International), May 18, 2010.
11. **Gaudet D**, Arsenault S, Côté JD, Dumont M, Lambert J, Paradis F, Rivard D. Anodized metal product with antimicrobial properties and method for producing the same. PCT/CA2013/000389, October 9, 2015
12. **Gaudet D**, Arsenault S, Côté JD, Dumont M, Lambert J, Paradis F, Rivard D. Traceable metallic products and metallic support for nanostorage. PCT/CA2014/000754, October17, 2014

#### 11. Publications

1. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med*. 2020 Jan 16;382(3):244-255.
2. **Gaudet D**, Durst R, Lepor N, Bakker-Arkema R, Bisgaier C, Masson L, Golden L, Kastelein JJ, Hegele RA, Stein E. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). *Am J Cardiol*. 2019 Dec 15;124(12):1876-1880.

3. Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, Bourbon M, Skiba PJ, Pordy R, Gipe DA, **Gaudet D**, Martin C. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. *Arterioscler Thromb Vasc Biol.* 2019 Nov;39(11):2248-2260.
4. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsso-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. *N Engl J Med.* 2019 Oct 3;381(14):1309-1320.
5. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet.* 2019 Sep 28;394(10204):1169-1180.
6. Laufs U, Banach M, Mancini GBJ, **Gaudet D**, Bloeden L, Sterling LR, Kelly S, Stroes E. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. *J Am Heart Assoc.* 2019 Apr 2;8(7):e011662.
7. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. *N Engl J Med.* 2019 Mar 14;380(11):1022-1032.
8. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *N Engl J Med.* 2019 Feb 21;380(8):752-762.
9. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2019 Jan 24;380(4):347-357.
10. Witztum, J, **Gaudet D**, Freedman SD, Vickie Alexander VJ, Digenio A, Williams K, QingQing Y, Hughes SG, Geary RS, Arca M, Stroes ES, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, O'Dea L, Bruckert E Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med.* 2019 Aug 8;381(6):531-542.
11. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet.* 2018 Oct 27;392(10157):1519-1529

12. **Gaudet D**, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A. Efficacy, safety and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the Hauser-RCT study. *J Clin Lipidol* 2018 Sep - Oct;12(5):1199-1207.
13. Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, **Gaudet D**, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Response by Kusters et al to letter regarding article "Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)". *Circulation*. 2018 Feb 6;137(6):641-642.
14. Stein EA, Dann EJ, Wiegman A, Skovby F, **Gaudet D**, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sundén M, Carisson SC, Raal FJ, Kastelein JJP. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. *J Am Coll Cardiol*. 2017 Aug 29;70(9):1162-1170.
15. Steinhagen-Thiessen E, **Gaudet D**, Stroes E, Soran H, Johnson C, Moulin P, Iotti G, Zibellini M, Ossenkippele B, Dippel M, Averna MR on behalf of the GENIALL Investigators. The role of registries in rare genetic lipid disorders : Review and introduction of the first global registry in lipoprotein lipase deficiency. *Atherosclerosis*. 2017 Jul;262 :146-153.
16. **Gaudet D**, Gipe D, A Khoury E, Pordy R, Sasiela WJ, Chan KC, Brisson D, Chyu KY, Banerjee P, Gromada J, Shah PK. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. *N Engl J Med*. 2017 Jul 20;377(3):296-297.
17. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman DM, Francis GA, Gagné C, **Gaudet D**, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study. *Circulation*. 2017 Jul 25;136(4):359-366.
18. Blom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, Shah PK, **Gaudet D**, Stefanutti C, Vigna GB, Larrey D, Bloedon LT, Foulds P, Rader DJ, Cuchel M. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. *Circulation*. 2017 Jul 18;136(3):332-335.
19. Lincoff AM, Nicholis SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McEneaney E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. *N Engl J Med*. 2017 May 18;376(20):1933-1942.
20. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017 May 4;376(18):1713-1722.
21. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jkema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS,

Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. *N Engl J Med.* 2017 Apr 20;376(16):1527-1539.

22. **Gaudet D**, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ. Effect of alirocumab on lipoprotein(a) over >1.5 years (from the phase 3 ODYSSEY Program). *Am J Cardiol.* 2017 Jan 1;119(1):40-46.